Kelley Boucher - 28 May 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief People Officer
Signature: /s/ David Watson, attorney-in-fact for Kelley Boucher
Issuer symbol: APLS
Transactions as of: 28 May 2025
Net transactions value: +$553,997
Form type: 4
Filing time: 29 May 2025, 11:46:30 UTC
Next filing: 11 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Boucher Kelley	Chief People Officer	C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM	/s/ David Watson, attorney-in-fact for Kelley Boucher	29 May 2025	0002070437

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+22,087		$0.000000	22,087	28 May 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$553,997	+32,976		$16.80	32,976	28 May 2025	Common Stock	32,976	$16.80	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This restricted stock unit was granted on May 28, 2025. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to her continued service as an officer, or upon later termination of her service.
F2	This represents a stock option award granted May 28, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.